Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02589171
Other study ID # HSC-MS-15-0668
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 12, 2016
Est. completion date April 25, 2018

Study information

Verified date August 2019
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the neoClose abdominal closure to the standard Carter-Thomason closure in a bariatric surgery gastric bypass population.


Description:

Both the neoClose abdominal closure to the standard Carter-Thomason closure will be used to close 12 mm camera port sites and 12 mm stapler port sites upon completion of a robotic assisted laparoscopic gastric bypass. The procedure requires a 12 mm port site be placed in the midline approximately 3 cm cephalad to the umbilicus and a second 12mm port site in the right mid abdomen. Port sites will be closed as defined as the inability to palpate a fascial defect and the incision being air tight upon carbon dioxide insufflation.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date April 25, 2018
Est. primary completion date April 25, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Morbid obesity (BMI > 35).

- Completed multimodality pre operative evaluation (Psychology, Nutrition, Support Groups).

- Approved for robotic assisted laparoscopic gastric bypass.

Exclusion Criteria:

- Previous midline laparotomy or weight loss procedure.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Neo Close Abdominal Closure
Neo Close Abdominal Closure
Carter Thomason Device
Carter Thomason Device

Locations

Country Name City State
United States The University of Texas Health Science Center at Houston Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston NeoSurgical Limited

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Technical Effectiveness as Assessed by Number of Sutures Required to Complete Closure at the Camera Port Site at the time of surgery
Primary Technical Effectiveness as Assessed by Number of Sutures Required to Complete Closure at the Stapler Port Site at the time of surgery
Primary Technical Effectiveness as Assessed by the Time Required to Complete Closure at the Camera Port Site at the time of surgery
Primary Technical Effectiveness as Assessed by the Time Required to Complete Closure at the Stapler Port Site at the time of surgery
Primary Technical Effectiveness as Assessed by Depth of Needle Penetration to Complete Closure at Both the Camera Port Site and Stapler Port Site at the time of surgery
Primary Technical Effectiveness as Assessed by Number of Participants With Surgical Site Occurrences Post-Operatively Surgical site occurrences include hematoma, seroma, or infection and were assessed by physical exam. immediately post op
Primary Technical Effectiveness as Assessed by Number of Participants With Surgical Site Occurrences Post-Operatively Surgical site occurrences include hematoma, seroma, or infection and were assessed by physical exam. 1 week
Primary Technical Effectiveness as Assessed by Number of Participants With Surgical Site Occurrences Post-Operatively Surgical site occurrences include hematoma, seroma, or infection and were assessed by physical exam. 6 weeks
Primary Technical Effectiveness as Assessed by Number of Participants With Presence of Port Site Hernia Post-operatively Abdominal ultrasound will be used to detect port site hernia. 6 weeks
Secondary Pain at the 12mm Camera Port Site as Assessed by a Visual Analog Scale Pain Score is based on a visual analog scale (VAS), with a range of 0 to 10. 0 indicates no pain and 10 indicates the most painful. day 1
Secondary Pain at the 12mm Camera Port Site as Assessed by a Visual Analog Scale Pain Score is based on a visual analog scale (VAS), with a range of 0 to 10. 0 indicates no pain and 10 indicates the most painful. 1 week
Secondary Pain at the 12mm Camera Port Site as Assessed by a Visual Analog Scale Pain Score is based on a visual analog scale (VAS), with a range of 0 to 10. 0 indicates no pain and 10 indicates the most painful. 6 weeks
Secondary Pain at the Stapler Port Site as Assessed by a Visual Analog Scale Pain Score is based on a visual analog scale (VAS), with a range of 0 to 10. 0 indicates no pain and 10 indicates the most painful. day 1
Secondary Pain at the Stapler Port Site as Assessed by a Visual Analog Scale Pain Score is based on a visual analog scale (VAS), with a range of 0 to 10. 0 indicates no pain and 10 indicates the most painful. 1 week
Secondary Pain at the Stapler Port Site as Assessed by a Visual Analog Scale Pain Score is based on a visual analog scale (VAS), with a range of 0 to 10. 0 indicates no pain and 10 indicates the most painful. 6 weeks
Secondary Pain as Assessed by Number of Participants Who Took Pain Medications week 1
Secondary Pain as Assessed by Number of Participants Who Took Pain Medications week 6
Secondary Hospital Stay Duration from the the time of hospital admission to the time of hospital discharge (about 1.29 to 2.95 days)
See also
  Status Clinical Trial Phase
Completed NCT03374189 - Prospective Study on a Novel Port-site Closure Device (EZ Close): Effectiveness and Comparison With Carter-Thomason N/A